New drug combo for returning lymphoma patients
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug combined with chemotherapy for patients whose T-cell lymphoma has come back or stopped responding to treatment. The goal is to see if this combination can help shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have been diagnosed with a type of lymphoma called PTCL that has returned or not responded to at least one prior treatment.
- You must have at least one tumor that can be measured on a scan (CT or MRI).
- You must be well enough to carry out daily activities (ECOG score 0-2).
- Your blood counts, kidney, and liver function must be within certain limits.
- If you are a woman who can still have children, you must agree to use two forms of birth control during and after the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a targeted drug (golidocitinib) with either a chemotherapy liposome or another targeted drug (chidamide) for people with peripheral T-cell lymphoma that has come back or stopped responding to treatment. The goal is to see if the combination works better than current options.
This trial tests if adding a new targeted drug (golidocitinib) to standard chemotherapy plus immunotherapy works better than the standard combo alone for people with advanced or non-nasal NK/T-cell lymphoma that hasn't been treated yet.
This trial tests a combination therapy with tazemetostat for people whose peripheral T-cell lymphoma has come back or hasn't responded to previous treatment. The goal is to see if this drug combination can help shrink tumors or slow the disease.
This trial tests a combination of two drugs, golidocitinib and pomalidomide, for people with a type of lymphoma called peripheral T-cell lymphoma (PTCL) that has come back or stopped responding to prior treatment. The goal is to see if this combination can help shrink tumors or slow the disease.
This trial is testing several new drug combinations for people with peripheral T-cell lymphoma that has come back or not responded to treatment. It aims to find new options that may work better.
This trial tests a new drug, golidocitinib, against a standard treatment chosen by your doctor for peripheral T-cell lymphoma that has come back or not responded to prior therapy. The goal is to see which approach works better for patients.
Hear when a new Peripheral T-cell Lymphomas (PTCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.